ClinicalTrials.gg
CompletedNCT05189093Updated Apr 20, 2026

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

A Phase 1/2 interventional study of Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection in Relapsed/Refractory Lymphoma, sponsored by Hangzhou Hanx Biopharmaceuticals, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Hangzhou Hanx Biopharmaceuticals, Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 276 studies in Lymphoma with a site in China — 103 open to participants now, 119 under way, 10 of them phase 3. Lymphoma · China.

Enrollment
115th of 232
48 · median 47
Started
2021
with 25 others
Phase 1/2
55 of 276
24 open now
Registered
144th of 276
by date

Among the 276 studies in Lymphoma with a site in China, this one is the 115th largest by enrollment of the 232 interventional ones that give a count, is one of 26 that started in 2021, is one of 55 in phase 1/2, and was the 144th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

103 of the 276 studies in Lymphoma with a site in China are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Lymphoma with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, open, single-arm phase I/II clinical study to evaluate the recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection in Chinese patients with relapsed/refractory lymphoma .

Read the detailed description

Phase Ib/II efficacy exploration and confirmation phase:

Four cohorts will be conducted in parallel to initially evaluate the recombinant humanized anti-CD47/PD-1 bifunctional anti HX009 injection.

The four cohorts in the efficacy exploration phase are:

Cohort 1: Relapsed/refractory diffuse large B-cell lymphoma; Cohort 2: relapsed/refractory peripheral T-cell lymphoma (except angioimmunoblastic T-cell lymphoma).

(except angioimmunoblastic T-cell lymphoma); Cohort 3: relapsed/refractory follicular lymphoma and relapsed/refractory marginal zone lymphoma; Cohort 4: relapsed/refractory EBV-positive non-Hodgkin's lymphoma. The study will refer to the "Guidelines for Data Monitoring Committees in Drug Clinical Trials (Trial)".

A data monitoring committee will be set up to provide continuous safety monitoring of the study and to provide advice on the dosage and dosing cycle, as well as on the follow-up of the study.

The committee will provide advice on the dosage and cycle of administration, as well as on the decision-making for subsequent extension studies.

Based on the safety data from this study at the 15 mg/kg dose level, during the efficacy exploration phase, the Each cohort will enroll 10-20 subjects, for a total of 4 cohorts, and each cohort will explore 1-2 dose levels, i.e., 10 mg/kg and 15 mg/kg, with an expected enrollment of 40-80 cases. The 10 mg/kg dose level will be enrolled first.

dose level first, and after discussion between the sponsor and the DMC, 15 mg/kg dose level will be enrolled if necessary.

The dose level of 15 mg/kg will be enrolled if necessary after discussion between the sponsor and the DMC. Based on the DMC analysis, the no-trend cohort will be enrolled in a maximum of 10 cases (with the possibility of stop enrollment midway).

The Phase II efficacy confirmation phase will select 1-2 cohorts from the 4 cohorts in the efficacy exploration phase of the study with better safety and efficacy.

1-2 indications with better efficacy to further confirm the efficacy and safety of HX009 injection. Based on the safety and efficacy data from Phase I of this study, the number of cases of subjects in the efficacy confirmation phase will be re-estimated based on statistical principles.

The number of cases of subjects in the validation phase will be re-estimated based on statistical

03

Conditions studied

  • Relapsed/Refractory Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participating in a clinical research study, being fully aware of and informed about the study and signing the Form (ICF).

    Willing to follow and capable of completing all study procedures;

  2. Male and Female. Age 18-65 years (including borderline values) in the dose-escalation phase; age 18-70 years (including borderline values) in the efficacy exploration and confirmation phase;
  3. lymphoma diagnosed according to the 5th edition of the WHO Classification Criteria for 2022 and meeting the following definition of .

    • The Phase Ib efficacy exploration phase will carry out cohort expansion according to the following tumors:

      • Patients with relapsed/refractory diffuse large B-cell lymphoma (including transformed DLBCL): need to have received systemic therapy with at least two standard regimens;
      • Relapsed/refractory peripheral T-cell lymphoma (except angioimmunoblastic T-cell lymphoma): Patients with relapsed/refractory peripheral T-cell lymphoma (except angioimmunoblastic T-cell lymphoma);
      • Relapsed/refractory follicular lymphoma and relapsed/refractory marginal zone lymphoma: at least two standard regimens of systemic therapy are required.
      • Relapsed/refractory EBV-positive non-Hodgkin's lymphoma: at least one systemic regimen is required.
  4. an (ECOG) Physical Strength Score of 0 to 2 within 14 days prior to first dose;
  5. expected survival ≥ 3 months;
  6. good major organ function, i.e., meeting the following criteria:

    • Blood system

      • (ANC) ≥1.5 × 10/L; with bone marrow invasion, ANC ≥1.0 × 10/L;
      • ≥75 × 10/L (without bone marrow invasion) and platelets ≥50.0 × 10/L (with bone marrow or spleen invasion);
      • (HB) ≥90 g/L; HB ≥80 g/L with bone marrow invasion;
    • Liver function

      • ≤ 2.0 x , or ≤ 5.0 x ULN for hepatic invasion;
      • Alanine aminotransferase ≤ 2.0 x ULN, or ≤ 5.0 x ULN in hepatic infestation;
      • Total ≤ 1.5 × ULN (except in Gilbert's syndrome or with hepatic or pancreatic invasion);
    • Renal function

      • ≥ 45 mL/min (calculated according to the Cockcroft-Gault formula, i.e., endogenous creatinine creatinine clearance = [(140 - age) × body weight (kg)]/[0.818 × serum creatinine (umol/L)], for women × 0.85 × calculated result. Sex according to the calculation × 0.85
    • Coagulation

      • (INR) ≤ 2 times ULN or activated partial thromboplastin time (APTT) ≤ 1.5 times ULN;
    • Cardiac function

      • Echocardiography: ≥ 45%.
  7. If previous antitumor therapy has been received, the following conditions need to be met:

    • Systemic radiation therapy at intervals of ≥3 weeks from the first dose, localized radiation therapy or bone at Radiation therapy for bone metastasis ≥ 2 weeks;
    • Prior chemotherapy, immunotherapy (CAR-T therapy, etc.), biologic therapy (tumor vaccines, cytokines or cancer-controlling growth factors), targeted therapies, antibody-coupled drugs ≥ 4 weeks or 5 half-lives (whichever is shorter) from the first dose. Previous chemotherapy (CART, etc.), immunotherapy (tumor vaccine, cytokine, or growth factor for cancer control), targeted therapy, antibody-coupled drug ≥ 4 weeks or 5 half-lives from first dose, whichever is shorter;
    • Previous treatment with antitumor Chinese medicine or proprietary Chinese medicine or medicine containing Chinese medicine ingredients for antitumor use and the interval between the first dose is ≥ 1 week;
  8. At least one according to Lugano criteria within 4 weeks prior to first dose; measurable Lesions: longest diameter of lymph node >15 mm, invasive lesions elsewhere >10 mm; previously treated lesions with localized therapy such as radiotherapy, if disease progression has been demonstrated and measurable lesions are met. Measurable lesions: longest diameter of lymph node >15 mm, other invasive lesions >10 mm; lesions previously treated with localized therapy, such as radiotherapy, are considered measurable if they have been shown to be progressive and meet the definition of measurable lesions.
  9. Female subjects must have a negative serum pregnancy test within 1 week prior to the first dose of study drug; female subjects or male subjects with a partner of agree to use effective (e.g., oral contraceptives, intrauterine devices) for a minimum of 12 months from the time of signing the informed consent form until the last dose of study drug.

Exclusion criteria

Exclusion criteria:

  1. Prior history of a other than skin cancer or carcinoma in situ that is not melanoma (e.g., cervical cancer, bladder cancer, breast cancer, etc.) unless disease-free status has been achieved for 3 years;
  2. failure to recover from adverse effects of prior therapy to a 5.0 grade score of ≤1, except for residual 3. active gastrointestinal ulcers
  3. active peptic ulcer, incomplete intestinal obstruction, active gastrointestinal bleeding and perforation;
  4. known history of hereditary or acquired hemolytic or bleeding disorders;
  5. subjects with primary or secondary central nervous system (CNS) lymphoma;
  6. patients who have received prior targeted therapy with 7 (including monoclonal antibodies, bispecific antibodies, etc.);
  7. patients who have received a blood transfusion or hematopoietic stimulating factor therapy, such as colony-stimulating factor, erythropoietin, erythropoietin, or other stimulating factors within 2 weeks prior to the start of treatment Erythropoietin, thrombopoietin, thrombopoietin, etc;
  8. Subjects with an active, or history of, disease that is likely to recur or is being treated (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis, etc.), or those at high risk (e.g., who have received organ transplants and need to be treated for immune-suppressant therapy); however, enrollment is permitted in subjects who have :

    • Type 1 diabetes mellitus that has stabilized with the use of fixed-dose insulin;
    • Autoimmune hypothyroidism and adrenal insufficiency requiring only hormone replacement therapy Adenosine insufficiency;
    • Skin diseases that do not require systemic therapy. For example, eczema, a rash that accounts for less than 10% of the body surface, without ophthalmologic symptoms (primarily dry eyes, blepharitis, conjunctivitis, lid adhesions Psoriasis without ophthalmologic symptoms (mainly dry eye, conjunctivitis, lid adhesions, keratitis, and uveitis);
  9. major surgery during the Screening Period 28 days prior to the first dose or minor surgery within 2 weeks (except diagnostic surgery), and any elective major surgery during the planned study period;
  10. Subjects requiring systemic (dose equivalent to >10 mg prednisone/day) or other medications within 14 days prior to the first dose or during the study period; the following conditions to >10 mg prednisone/day) or other immunosuppressive medications within 14 days prior to the first dose or during the study period; the following were Enrollment is permitted:

    • Subjects on topical topical or inhaled glucocorticoids;
    • Short-term (≤7 days) use of glucocorticoids for prophylaxis or treatment of non-autoimmune allergic diseases. allergic diseases;
    • Corticosteroids for the replacement therapy of adrenal insufficiency;
    • If high-dose glucocorticoid therapy is urgently needed prior to initiation of study treatment to If high-dose glucocorticoid therapy is urgently needed to control symptoms of lymphoma prior to initiation of study treatment, a tumor evaluation must be completed prior to initiation of treatment.
  11. Currently suffers from a serious lung disease requiring treatment or from a previous serious lung disease, interstitial lung disease, interstitial pneumonia. interstitial lung disease, interstitial pneumonia, pulmonary fibrosis, radiation pneumonitis requiring hormone therapy, etc;
  12. uncontrolled systemic diseases such as cardiovascular diseases (severe arrhythmia, unstable angina or myocardial infarction within 6 months, etc.) Uncontrolled systemic diseases, such as cardiovascular diseases (severe arrhythmia, unstable angina or myocardial infarction within 6 months), diabetes mellitus, hypertension, etc. 13;
  13. arterial or venous thrombosis or embolic events within 3 months prior to the first dose, such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism;
  14. being positive for or having other acquired, congenital immunodeficiency diseases. History of organ transplantation or stem cell transplantation;
  15. active tuberculosis disease or latent tuberculosis infection;
  16. Subjects with active or . Hepatitis B patients: HBsAg or HBcAg positive. Except for the following:

    • If HBcAg positive, not associated with HBsAg positivity, negative DNA test (\<20 IU or lower limit of local laboratory normal) and subject to periodic DNA testing during the study period;
    • Cured Hepatitis C subjects (negative HCV RNA test);
  17. subjects with severe active infection within 2 weeks prior to the first dose of study drug;
  18. subjects with a known history of severe allergic reactions to large protein preparations or to any of the components of the test drug (CTC); or 18. a known subject with a previous severe allergic reaction (CTCAE 5.0 ≥ 3) to a large protein preparation or to any of the components of the test drug;
  19. participation in a clinical trial of another drug within 4 weeks prior to the first dose;
  20. alcohol dependence or a history of drug or substance abuse within the last 1 year
  21. previous history of definite neurological or psychiatric disorders, such as epilepsy, dementia, poor adherence;
  22. women who are pregnant or breastfeeding;
  23. Subjects who have received any live or attenuated vaccine within 28 days prior to the first dose of study drug. If enrolled, subjects must not receive any live or attenuated vaccine during the study period or within 180 days of the last dose of HX009. . Subjects vaccinated with inactivated, mRNA, viral vector, and labeled protein COVID-19 vaccines are eligible to participate in the study. Subjects vaccinated with inactivated, mRNA, viral vector and labeled protein COVID-19 vaccines are eligible to participate in the study and the vaccination timeline should follow local guidelines;
  24. subjects who, in the opinion of the Investigator, are otherwise unsuitable for participation in this trial.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    phase I dose escalation part,Phase II efficacy exploratory part and the efficacy confirmation part

    Phase Ib/II efficacy exploration and confirmation phase: Four cohorts will be conducted in parallel to initially evaluate the recombinant humanized anti-CD47/PD-1 bifunctional anti HX009 injection. The four cohorts in the efficacy exploration phase are: Cohort 1: Relapsed/refractory diffuse large B-cell lymphoma; Cohort 2: relapsed/refractory peripheral T-cell lymphoma (except angioimmunoblastic T-cell lymphoma). (except angioimmunoblastic T-cell lymphoma); Cohort 3: relapsed/refractory follicular lymphoma and relapsed/refractory marginal zone lymphoma; Cohort 4: relapsed/refractory EBV-positive non-Hodgkin's lymphoma.

    Drug: Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection

Interventions

  • DrugRecombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection

    There will be a total of 4 cohorts, each cohort will explore 1-2 dose levels, i.e. 10 mg/kg and 15 mg/kg, with an expected enrollment of 40-80 cases. The 10 mg/kg dose level will be enrolled first, the After discussion between the sponsor and the DSC, the 15 mg/kg dose level will be enrolled if necessary. Based on the DMC analysis, the no-trend cohort will be enrolled in a maximum of 10 cases (with the possibility of stopping enrollment halfway through).

06

What researchers measure

Primary outcomes

  1. Objective response rate(ORR) of patients with solid tumors treated with HX009 per Investigator Assessment

    Objective response rate (ORR) assessed according to the evaluation criteria of each tumor type

    Time frame: Tumor assessment every 6 weeks (±7 days),up to 1 year

Secondary outcomes

  1. 6 months and 12 months progression-free survival (PFS )

    PFS is defined as the time from the start of the first dose and the first documented disease progression using RECIST 1.1 criteria or death of any cause.

    Time frame: Approximately 1 year

  2. Complete Remission Rate (CRR)

    Disappearance of all target lesions, no new lesions appearing

    Time frame: Approximately 1 year

  3. Duration of Remission (DOR)

    The DOR is defined as the time from the first recorded response (CR or PR) to the first recorded tumor progression or death due to any cause.

    Time frame: Tumor assessment every 6 weeks (±7 days),up to 1year

  4. Disease Control Rate (DCR)

    The DCR is defined as the percentage of participants in the analysis population who had a confirmed Complete Response, or Partial Response, or Stable Disease using RECIST 1.1 criteria.

    Time frame: Tumor assessment every 6 weeks (±7 days),up to 1 year

  5. Incidence and severity of AE and SAE, laboratory tests and vital signs(Including :heart rate, blood pressure, respiration,temperature.);

    Adverse events (AEs) determined by the investigator are recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0).

    Time frame: All AEs up to 28 days after the last dose of study drug,Or other tumor treatment programs have been started (the earlier date shall prevail); irAE should be followed up to 90 days after the last dose, or other tumor treatment programs have been started

  6. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: Tmax

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  7. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: Tmin

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  8. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: Cmin

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  9. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: Cavg

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  10. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: AUCss

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  11. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: t1/2

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  12. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: λz

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  13. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: CLss/F

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  14. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: Vz/F

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  15. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: DF

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  16. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: AUC0-t

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  17. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: AUC0-∞

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  18. Pharmacokinetic parameters of recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection: AUCext%

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  19. Peak plasma concentration (Cmax) of HX009 in patients with relapsed/refractory lymphoma

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  20. Antidrug antibodies (ADA)

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

  21. Neutralizing antibodies (Nab) after treatment (ADA-positive individuals only)

    Key pharmacokinetic parameter

    Time frame: Approximately 1 year

07

Study locations

1 site
  • Cancer Hospital Chinese Academy of Medical Sciense
    Beijing, Beijing Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jun 2025, 41 months.

Of 66 industry-sponsored phase 1/2 interventional studies under Lymphoma, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 87. This study's 41 months is below that.

Counting every sponsor, half of 143 studies reached it within 74 months; a quarter within 48 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2021
First posted
Jan 12, 2022
StartActual
Dec 31, 2021
Primary completionActual
Jun 25, 2025
CompletionActual
Dec 31, 2025
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05189093
Lead sponsor
Hangzhou Hanx Biopharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Jan 12, 2022
Start date
Dec 31, 2021
Primary completion
Jun 25, 2025
Completion
Dec 31, 2025
Last update
Apr 20, 2026

Study contacts

Yuankai Shi
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion